etanidazole has been researched along with Peripheral Nerve Diseases in 9 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A study was undertaken adding the alkylating agent sensitizer etanidazole to intravenous melphalan and oral prednisone for patients with multiple myeloma." | 9.07 | Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. ( Buswell, L; Coleman, CN; Kalish, LA; Shulman, LN, 1994) |
| "A study was undertaken adding the alkylating agent sensitizer etanidazole to intravenous melphalan and oral prednisone for patients with multiple myeloma." | 5.07 | Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. ( Buswell, L; Coleman, CN; Kalish, LA; Shulman, LN, 1994) |
| "Etanidazole was administered intravenously at a dose of 2 g/m2 three times per week for a total of 30 g/m2 during the course of thoracic radiation that delivered 50." | 2.69 | Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study. ( Belch, A; Hanson, J; Hewitt, J; Kinney, B; Palmer, M; Urtasun, RC, 1998) |
| "To prospectively evaluate the pharmacokinetic monitoring and drug dose adjustment of Etanidazole (Eta) in patients treated on the RTOG randomized trial for Stage III and IV head and neck cancer." | 2.68 | Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial. ( Buswell, L; Coleman, CN; Lee, DJ; Noll, L; Pajak, TF; Riese, NE; Stetz, J, 1997) |
| " The secondary goal was to prospectively evaluate the utility of pharmacokinetic monitoring and dose-modification of the incidence and severity of the dose-limiting peripheral neurotoxicity." | 2.67 | The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer. ( Buswell, L; Coleman, CN; Noll, L; Riese, N; Rose, MA, 1992) |
| "Complete pharmacological data from 71 patients treated on the phase I trial of SR 2508 were analyzed to see if the dose-limiting toxicity of peripheral neuropathy is related to the individual patient's pharmacokinetic profile." | 1.27 | Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. ( Blaschke, T; Coleman, CN; Cox, RS; Halsey, J; Hancock, S; Hirst, VK; Howes, AE; Pajak, T; Urtasun, RC; Wasserman, TH, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buswell, L | 4 |
| Recht, A | 1 |
| Clark, J | 1 |
| Ravikumar, T | 1 |
| Busse, PM | 1 |
| Coleman, CN | 7 |
| Shulman, LN | 1 |
| Kalish, LA | 1 |
| Riese, NE | 1 |
| Noll, L | 3 |
| Pajak, TF | 1 |
| Stetz, J | 1 |
| Lee, DJ | 1 |
| Urtasun, RC | 4 |
| Palmer, M | 1 |
| Kinney, B | 1 |
| Belch, A | 1 |
| Hewitt, J | 1 |
| Hanson, J | 1 |
| Riese, N | 1 |
| Rose, MA | 1 |
| Wasserman, TH | 3 |
| Halsey, J | 3 |
| Hancock, S | 3 |
| Phillips, TL | 2 |
| Bleehen, NM | 1 |
| Newman, HF | 1 |
| Maughan, TS | 1 |
| Workman, P | 1 |
| Hirst, VK | 2 |
| Cox, RS | 1 |
| Blaschke, T | 1 |
| Howes, AE | 1 |
| Pajak, T | 1 |
7 trials available for etanidazole and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etanidazole; Humans; Infusions, Intravenous; Melphal | 1994 |
Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial.
Topics: Antineoplastic Agents; Area Under Curve; Disease-Free Survival; Etanidazole; Head and Neck Neoplasms | 1997 |
Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality | 1998 |
The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Male; Nitroimidazol | 1992 |
Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Topics: Adult; Canada; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Infusions, Intraveno | 1990 |
A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Topics: Drug Combinations; Etanidazole; Humans; Neoplasms; Nitroimidazoles; Peripheral Nervous System Diseas | 1989 |
2 other studies available for etanidazole and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
Topics: Drug Administration Schedule; Drug Evaluation; Etanidazole; Humans; Nitroimidazoles; Peripheral Nerv | 1986 |
Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Etanidazole; Humans; Kinetics; Mison | 1987 |